This article is more than 5 years old. Information may no longer be current.

Zepatier yields high SVR12 in real-world VA cohort

AMSTERDAM — Zepatier was associated with SVR12 rates above 95% in a real-world, Veterans Affairs cohort, according to data presented at the International Liver Congress.

Amy Puenpatom, MD, of the center for observational and real-world evidence at Merck Sharp & Dohme Corp., said that the current study is the largest study of Zepatier (grazoprevir/elbasvir, Merck) to date. The current retrospective database analysis included patients from Feb. 1, 2016, through Aug. 1, 2016. There were 2,436 patients in an evaluable population and 2,257 patients in a per-protocol population. Puenpatom focused her comments on the evaluable population.

Results indicated a 95.6% SVR12 rate in the evaluable population and  97% for the per-protocol population.

Sex, race or ethnicity failed to impact SVR12 rates, with even black patients reaching 96%. Genotype also had no impact on treatment, ranging from 93.4% to 100% for genotypes 1a, 1b, 2, 3, 4, or unknown genotype.

Similarly, cirrhosis, baseline viral load, previous treatment experience status, HIV status, alcohol or drug use status, or chronic kidney disease status did not impact SVR12. The lowest rate was reported among patients with Harvoni (ledipasvir/sofosbuvir, Gilead) experience, at 82%.

Puenpatom noted that about 95% of the cohort had genotype 1 disease and that 20% had treatment experience.

“Our study shows that this regimen was highly effective,” she said. “SVR rates were high across subgroups regardless of gender/ethnicity, presence of cirrhosis, renal impairment or HIV.” – by Rob Volansky

Reference:

Puenpatom A, et al. Abstract PS-095. Presented at: International Liver Congress; April 19-24, 2017; Amsterdam. 

Disclosure: Puenpatom reports being a stockholder and employee of Merck & Co.